This Swiss Startup's Gene Editing Breakthrough Could Change Medicine Forever

Jan de Vries · 2026-07-22

### A New Dawn for Gene Editing Imagine a single injection that could cure genetic diseases without the need for chemotherapy or stem cell transplants. That's exactly what Immitra Bio, a Zurich-based startup, is working on. And they just got a major vote of confidence from investors. The company announced it has raised $2.68 million in an upsized pre-seed round. That's about 2.4 million Swiss francs. The funding came from a mix of venture capital firms and private investors, with Backbone Ventures leading the charge and OCCIDENT co-leading. Other backers include Another VC, Kickfund, Venture Kick, Zurcher Kantonalbank, FONGIT, ETH Foundation, and several private individuals. ### Why This Matters Current gene therapies are a mixed bag. They work, but they're incredibly complex. Most involve removing cells from a patient, editing them in a lab, and then putting them back. This ex-vivo approach is toxic, slow, and expensive. It also requires chemotherapy to prepare the body for new cells. Immitra Bio wants to flip that model. Their platform is designed for in-vivo editing, meaning the therapy happens inside the body. No cell extraction. No chemotherapy. Just one off-the-shelf injection that targets the root cause of the disease. ### The Technology Behind the Hype Founded in 2024 by Jan Nelis, Amir Taheri, and Jacob Corn, Immitra Bio is building a mutation-agnostic platform. That's a fancy way of saying their technology can correct genetic errors regardless of the specific mutation. It's like having a universal key that fits any lock. Their approach combines a novel gene editing mechanism with a digital target discovery platform. This allows them to identify and develop treatments for a wide range of genetic disorders quickly. Instead of creating personalized therapies for each patient, they aim to produce standardized drug formulations that work for everyone with a given disease. ### What Investors Are Saying Paul Sunzenauer from OCCIDENT put it well: "Recent advances have validated the potential of curative genetic medicine, but current approaches still face significant challenges. Immitra Bio's platform addresses these head-on." He highlighted the combination of non-viral delivery and mutation-independent therapy as a potential game-changer. ### Where the Money Will Go The fresh capital will primarily fund preclinical studies for Immitra Bio's lead candidate, IB-003. This is a one-time curative treatment for an inherited form of anemia. The company will also use the funds to expand its pipeline and refine its platform. ### The Big Picture Gene editing has been hailed as the future of medicine, but the road to commercialization has been bumpy. Immitra Bio's approach could finally make these therapies scalable and accessible. If successful, they could transform how we treat everything from sickle cell disease to cystic fibrosis. Of course, it's early days. Preclinical results are promising, but human trials are still ahead. Still, with a strong team and a clear vision, Immitra Bio is one to watch. ### Key Takeaways - Immitra Bio raised $2.68 million in pre-seed funding - Their in-vivo platform avoids chemotherapy and cell transplants - The technology is mutation-agnostic, targeting many genetic diseases - Lead candidate IB-003 targets inherited anemia - Investors include Backbone Ventures, OCCIDENT, and others